Breaking News

LGM Pharma Reports Growth in First Year of CDMO Operations

Booked 13 CDMO commercial manufacturing projects and 49 development service projects.

LGM Pharma reported strong growth in 2022 in both its active pharmaceutical ingredient (API) division and its new contract development and manufacturing organization (CDMO) division.  LGM acquired its CDMO division in 2020, with full operational integration accomplished in late 2021 for commercial manufacturing and for the two newly-created CDMO service segments, Analytical Testing Services (ATS) and Drug Product Research & Development (R&D). According to the company, strong demand...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters